On June 24, 2025, Genprex, Inc. announced positive preclinical results for GPX-002, a diabetes gene therapy, showing that it effectively converted alpha cells to beta-like cells in animal models, improving glucose control for up to three months. Researchers are continuing studies to further evaluate its effects and required immune suppression.